Parabacteroides Distasonis

Overview

Parabacteroides distasonis is a Gram-negative obligate anaerobe formerly classified within Bacteroides. It is a core member of the healthy human gut microbiome, typically found in the colon where it contributes to polysaccharide degradation and bile acid metabolism.

Metal Dependencies

P. distasonis requires iron for central metabolic enzymes and zinc for its hydrolase activities. Paradoxically, the iron-rich inflammatory environments that favor Proteobacteria tend to suppress P. distasonis, suggesting it is outcompeted when nutritional immunity breaks down and luminal iron rises.

Ecological Role

In a balanced gut, P. distasonis performs critical bile acid biotransformations through bile salt hydrolase activity, converting primary bile acids to secondary forms that regulate host metabolism and immune signaling. Its depletion shifts the bile acid pool toward pro-inflammatory and pro-tumorigenic profiles. The organism also produces short-chain fatty acids that support epithelial barrier integrity.

Conditions Associated

Depletion of P. distasonis is consistently reported in obesity, type 2 diabetes, and inflammatory bowel disease. Animal studies show that oral supplementation with P. distasonis reduces adiposity, improves glucose tolerance, and attenuates intestinal inflammation — positioning it as a candidate next-generation probiotic.

Cross-References

References (5)

  1. Giorgio Casaburi, Jingjing Wei, Sufyan Kazi et al. (2022). Casaburi 2022 — Formate as a metabolic driver of NEC: integrated metagenomics and targeted metabolomics. Frontiers in Pediatrics. doi:10.3389/fped.2022.893059
  2. Matteo Bronzini, Alessandro Maglione, Rachele Rosso et al. (2023). Feeding the gut microbiome: impact on multiple sclerosis. Frontiers in Immunology. doi:10.3389/fimmu.2023.1176016
  3. Esraa Mohsen, Hesham Haffez, Sandra Ahmed et al. (2025). Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System. Molecular Neurobiology. doi:10.1007/s12035-025-04728-5
  4. Ilze Elbere, Ivars Silamikelis, Ilze Izabella Dindune et al. (2020). Elbere 2020 — Baseline Gut Microbiome Composition Predicts Metformin Therapy Short-Term Efficacy in Newly Diagnosed Type 2 Diabetes Patients. PLoS ONE. doi:10.1371/journal.pone.0241338
  5. Dorothea Katharina Hoffelner, Tim Hendrikx (2025). Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease. Frontiers in Cardiovascular Medicine. doi:10.3389/fcvm.2025.1631841